Hypercoagulability state in hip and knee surgery: Influence of ABO antigenic system and allogenic transfusion

Transfusion Science

Volumn 20, Issue 1, 1999, Pages 17-20

  Iturbe, Teodoro ^a   Cornudella, Rosa ^a   De Miguel, Roberto ^a   Olave, Teresa ^a   Moreno, José Antonio ^a   Callén, Luis ^a   Gutiérrez, Martín ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; ENOXAPARIN; NADROPARIN; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX;

ADULT; AGED; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIP SURGERY; HUMAN; HYPERCOAGULABILITY; KNEE SURGERY; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD TRANSFUSION; FEMALE; HUMANS; ISOANTIGENS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THROMBOPHILIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032902785     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(98)00086-1     Document Type: Article

References (15)

1. Jack H, Sloe D, Westerholm B, Inman WHW, Vessey MP, Shapiro S, Lewis G, Worcester J. Venous Thromboembolic disease and ABO blood type. Lancet 1969;i:539-542.
2. Talbot S, Ryrie D, Walkley EJ, Langman MJS. ABO blood groups and venous thromboembolic disease. Lancet. 1970;i:1257-1259.
3. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep vein thrombosis within a defined urban population. J. Intern. Med. 1992;232:155-160.
4. Salvati EA, Lachiewicz P. Thromboembolism following total hip-replacement arthroplasty. The efficacy of dextran-warfarin in prophylaxis. J. Bone Joint Surg. 1976;58-A:921-925.
5. Koster T, Blann AD, Briët E, Vandenbroucke J, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995;345:152-155.
6. Gill JC, Endress-Brooks J, Bauer PJ, Marks WJ Jr., Montgomery RR. The effect of ABO blood groups on the diagnosis of von Willebrand disease. Blood. 1987;69:1691-1695.
7. Caekebeke-Peerlinck KMJ, Koster T, Briët E. Bleeding time, blood groups and von Willebrand factor. Br. J. Haematol. 1989;73:217-220.
8. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N. Engl. J. Med. 1994;331:1601-1606.
9. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N. Engl. J.Med. 1996;335:701-707.
10. European Consensus Statement. Prevention of venous thromboembolism. Int. Angiol. 1992;11:151-159.
11. Sikorski JM, Hampson WG, Staddon GE. The natural history and aetiology of deep vein thrombosis after hip replacement. J Bone Joint Surg. 1981;63-B:171-177.
12. Nowak-Gottl U, Schaudin E, Hoffmann C, Eckhoff-Donovan S, Merthes N. Intraoperative clotting factor dilution and activated hemostasis in children with Ewinǵs sarcoma or osteosarcoma: a prospective longitudinal study. Haematologica. 1995;80(4):311-317.
13. Menges T, Rupp D, van Lessen A, Hempelmann G. Measures for reducing the use of homologous blood. Effects on blood coagulation during total endoprothesis. Anaesthesist. 1992;41(19):27-33.
14. Utada K, Matayoshi I, Sumi C, Itaya M, Miyawasaki H, Ito M, Tamura H, Mitsukuji I. Aprotinin 2 million KIU reduces perioperative blood loss in patients undergoing primary total hip replacement. Masui. 1997;46(1):77-82.
15. Murkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth. Analg. 1995;80(2):343-348.